In yesterday’s Wall Street session, Eli Lilly and Company (NYSE:LLY) shares traded at $526.23, up 0.89% from the previous session.
As of this writing, 30 analysts cover Eli Lilly and Company (NYSE:LLY). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $633.00 and a low of $300.00, we find $526.00. Given the previous closing price of $521.60, this indicates a potential upside of 0.84 percent. LLY stock price is now 16.39% away from the 50-day moving average and 36.99% away from the 200-day moving average. The market capitalization of the company currently stands at $499.17B.
There are 6 analysts who have given it a hold rating, whereas 21 have given it a buy rating. Brokers who have rated the stock have averaged $527.77 as their price target over the next twelve months.
With the price target enhanced from $408 to $615, Jefferies Upgraded its rating from Hold to Buy for Eli Lilly and Company (NYSE: LLY).
In other news, LILLY ENDOWMENT INC, 10% Owner sold 204,409 shares of the company’s stock on Aug 08. The stock was sold for $107,056,405 at an average price of $523.74. Upon completion of the transaction, the 10% Owner now directly owns 100,823,810 shares in the company, valued at $53.06 billion. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 21, 10% Owner LILLY ENDOWMENT INC sold 591 shares of the business’s stock. A total of $275,773 was realized by selling the stock at an average price of $466.62. This leaves the insider owning 101,028,219 shares of the company worth $53.16 billion. Insiders disposed of 2,954,037 shares of company stock worth roughly $1.55 billion over the past 1 year. A total of 10.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LLY stock. A new stake in Eli Lilly and Company shares was purchased by EDGEWOOD MANAGEMENT LLC during the first quarter worth $1,116,339,000. SWS PARTNERS invested $238,866,000 in shares of LLY during the first quarter. In the first quarter, ORBIMED ADVISORS LLC acquired a new stake in Eli Lilly and Company valued at approximately $97,879,000. SOFINNOVA INVESTMENTS, INC. acquired a new stake in LLY for approximately $72,146,000. ARTEMIS INVESTMENT MANAGEMENT LLP purchased a new stake in LLY valued at around $60,933,000 in the second quarter. In total, there are 3,403 active investors with 84.80% ownership of the company’s stock.
Wednesday morning saw Eli Lilly and Company (NYSE: LLY) opened at $520.37. During the past 12 months, Eli Lilly and Company has had a low of $296.32 and a high of $538.00. As of last week, the company has a debt-to-equity ratio of 1.69, a current ratio of 1.30, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $510.36B, which is based on a 83.54 price-to-earnings ratio, a 3.48 price-to-earnings-growth ratio, and a beta of 0.32. The fifty day moving average price for LLY is $454.13 and a two-hundred day moving average price translates $385.12 for the stock.
The latest earnings results from Eli Lilly and Company (NYSE: LLY) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.84, beating analysts’ expectations of $1.73 by 0.11. This compares to $1.05 EPS in the same period last year. The net profit margin was 20.50% and return on equity was 56.20% for LLY. The company reported revenue of $8.31 billion for the quarter, compared to $6.49 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 28.11 percent. For the current quarter, analysts expect LLY to generate $7.07B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/08/2023. Investors who held shares on 08/15/2023 were paid a $1.13 dividend. On an annualized basis, this represents a $4.52 dividend and a 0.86% percent yield. There was an ex-dividend date of 08/14/2023 for this dividend. In terms of dividend payout ratio, LLY is presently at 64.50%.
Eli Lilly and Company(LLY) Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
